Time equals money. In the pharmaceutical development world, this axiom is literal. The financial cost of a delayed clinical trial is upwards of $680,000 per day. More significantly, the lost opportunity costs of being late to market - such as market exclusivity, leadership positioning, or thought leader and advocacy relationships - are even higher. Pharmaceutical performance and success are closely linked to the reduction of drug approval time.